Ruxotemitide
Tier C — Watch / tradeRuxotemitide
Targets：BCL2
Brand：Oncopore
Indications (approved)：Basal cell carcinoma, Melanoma, Sarcoma, Lymphoma, Breast cancer, 三阴性乳腺癌, Solid tumour, Head and neck cancer
Regional status
Synthetic routes & intermediates4 routes
Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.
| Code | CAS No. | Intermediate |
|---|---|---|
| (I)629485-1-a,(I)629485-1-c | 105047-45-8 | Fmoc-L-Lys-OH |
| (II)629485-1-a | - | Resin bound (9-fluorenyl)methyl [(2S)-1,6-diamino-1-oxohexan-2-yl]carbamate |
| (III)629485-1-a | 201484-50-6 | N-[[(9-Fluorenyl)methoxy]carbonyl]-beta-phenyl-L-phenylalanine |
| (IV)629485-1-a | - | Resin bound N-[[(9-fluorenyl)methoxy]carbonyl]-beta-phenyl-L-phenylalanyl-L-lysinamide |
| (V)629485-1-a,(V)629485-1-b | 86123-11-7 | N-[(9H-Fluoren-9-ylmethoxy)carbonyl]-D-tryptophan |
| (VI)629485-1-a | - | Resin bound N-[[(9-fluorenyl)methoxy]carbonyl]-L-tryptophyl-beta-phenyl-L-phenylalanyl-L-lysinamide |
| (VII)629485-1-a | - | Resin bound N2-[[(9-fluorenyl)methoxy]carbonyl]-L-lysyl-L-tryptophyl-beta-phenyl-L-phenylalanyl-L-lysinamide |
| (VIII)629485-1-a,(VIII)629485-1-b | - | Resin bound N2-[[(9-fluorenyl)methoxy]carbonyl]-L-lysyl-L-lysyl-L-tryptophyl-beta-phenyl-L-phenylalanyl-L-lysinamide |
| Code | CAS No. | Intermediate |
|---|---|---|
| (V)629485-1-a,(V)629485-1-b | 86123-11-7 | N-[(9H-Fluoren-9-ylmethoxy)carbonyl]-D-tryptophan |
| (VIII)629485-1-a,(VIII)629485-1-b | - | Resin bound N2-[[(9-fluorenyl)methoxy]carbonyl]-L-lysyl-L-lysyl-L-tryptophyl-beta-phenyl-L-phenylalanyl-L-lysinamide |
| (IX)629485-1-b | - | Resin bound N-[[(9-fluorenyl)methoxy]carbonyl]-L-tryptophyl-L-lysyl-L-lysyl-L-tryptophyl-beta-phenyl-L-phenylalanyl-L-lysinamide |
| (X)629485-1-b,(X)629485-1-c | - | Resin bound N-[[(9-fluorenyl)methoxy]carbonyl]-L-tryptophyl-L-tryptophyl-L-lysyl-L-lysyl-L-tryptophyl-beta-phenyl-L-phenylalanyl-L-lysinamide |
| Code | CAS No. | Intermediate |
|---|---|---|
| (I)629485-1-a,(I)629485-1-c | 105047-45-8 | Fmoc-L-Lys-OH |
| (X)629485-1-b,(X)629485-1-c | - | Resin bound N-[[(9-fluorenyl)methoxy]carbonyl]-L-tryptophyl-L-tryptophyl-L-lysyl-L-lysyl-L-tryptophyl-beta-phenyl-L-phenylalanyl-L-lysinamide |
| (XI)629485-1-c | - | Resin bound N2-[[(9-fluorenyl)methoxy]carbonyl]-L-lysyl-L-tryptophyl-L-tryptophyl-L-lysyl-L-lysyl-L-tryptophyl-beta-phenyl-L-phenylalanyl-L-lysinamide |
| (XII)629485-1-c,(XII)629485-1-d | - | Resin bound N2-[[(9-fluorenyl)methoxy]carbonyl]-L-lysyl-L-lysyl-L-tryptophyl-L-tryptophyl-L-lysyl-L-lysyl-L-tryptophyl-beta-phenyl-L-phenylalanyl-L-lysinamide |
| Code | CAS No. | Intermediate |
|---|---|---|
| (XII)629485-1-c,(XII)629485-1-d | - | Resin bound N2-[[(9-fluorenyl)methoxy]carbonyl]-L-lysyl-L-lysyl-L-tryptophyl-L-tryptophyl-L-lysyl-L-lysyl-L-tryptophyl-beta-phenyl-L-phenylalanyl-L-lysinamide |
Frequently asked questions
What are the approved indications of Ruxotemitide?
Approved indications include: Basal cell carcinoma, Melanoma, Sarcoma, Lymphoma, Breast cancer, 三阴性乳腺癌, Solid tumour, Head and neck cancer.
When does the Ruxotemitide patent expire?
No public expiry year is available for Ruxotemitide yet; this page updates once verified.
How many synthesis routes are recorded for Ruxotemitide?
4 synthesis routes are recorded; the shortest is 1 steps with / total yield. Intermediates in each route carry codes and CAS numbers.
Where can I buy Ruxotemitide intermediates?
All intermediates in Ruxotemitide routes have CAS profiles — you can submit an RFQ per CAS and it enters the Unibest matching pool.
How do I get a quote for Ruxotemitide intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-08